NEW DELHI: Sun Pharma Advanced Research Company (SPARC) is formulating new drugs for allergies, inflammations, neuropathy and seizures as part of its drug discovery programme.
In the same move, the company is undertaking various studies to look into the safety and efficacy of its molecules SUN-1334H, SUN-597 and SUN-44, as expressed by Sun Pharma Advanced Research Company CMD Dilip Shanghvi.
“Our lead molecule SUN-133H is an anti-allergic for use in seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria and allergic conjunctivitis. It is being developed for oral use as well as topical use, as eye drops and nasal drops,” Shanghvi added while addressing the 7th annual general meeting (AGM) of the company.
Already, the company has completed the phase II study to assess the efficacy of the opthalmic formulation of the molecule in the United States in which it was shown to be safe and well tolerated.
Another molecule SUN-597 is also undergoing clinical trials for the treatment of inflammation of airway, skin, eye and gastrointestinal tract.
Moreover, the company is also developing 'SUN-44' a pro-drug for the treatment of neuropathy and seizures. The Indian government has approved Investigational New Drug (IND) and phase-I is planned in the current fiscal (2012-13).